S-1/A: Nuwellis Eyes $8 Million in Unit Offering to Bolster Commercialization Efforts

Nuwellis, Inc. announces a proposed offering of up to 16,326,530 units to raise up to $8 million for working capital and commercialization.

Summary

• Nuwellis, Inc. is planning to offer up to 16,326,530 units, each consisting of one share of common stock and one common warrant, aiming to raise up to $8 million.
• The assumed offering price is $0.49 per unit, based on the closing price of the common stock on January 26, 2024.
• Common warrants will have an exercise price of $0.49 per share and expire five years from issuance.
• Pre-funded units, consisting of a pre-funded warrant and a common warrant, are also being offered to certain purchasers.
• The purchase price of each pre-funded unit will be the unit price minus $0.0001, with an exercise price of $0.0001 per share for the pre-funded warrants.
• The offering is on a reasonable best efforts basis with no minimum offering requirement.
• Net proceeds are intended for working capital and general corporate purposes, including commercialization efforts.
• Lake Street Capital Markets and Maxim Group LLC are acting as placement agents for the offering.
• The company's stock is currently listed on the Nasdaq Capital Market under the symbol NUWE.
• Nuwellis faces a Nasdaq compliance issue due to its stock price falling below $1.00, with a deadline of June 4, 2024, to regain compliance.

Sentiment

Score: 5

Explanation: The document is primarily factual, outlining the terms of the proposed offering and providing background information on the company and its market. While it highlights potential benefits of the Aquadex system, it also acknowledges risks and uncertainties, resulting in a neutral sentiment score.

Positives

• The offering aims to strengthen the company's financial position for ongoing commercialization efforts.
• The Aquadex System has demonstrated clinical and economic benefits in treating fluid overload.
• The company is expanding its focus to include critical care and pediatrics, representing significant market opportunities.
• The company is developing a dedicated CRRT device for pediatric patients.
• The company has a Supply and Collaboration Agreement with DaVita to pilot the Aquadex system.
• SeaStar received an Approvable Letter from the FDA for its SCD-PED.

Negatives

• The offering is on a 'reasonable best efforts' basis, meaning there's no guarantee all units will be sold.
• The company faces a Nasdaq compliance issue due to its stock price falling below $1.00.
• The company has incurred operating losses since its inception and anticipates that it will continue to incur operating losses in the near-term.
• The company's near-term prospects are highly dependent on revenues from a single product, the Aquadex System.

Risks

• The offering may not raise the amount of capital the company believes is required.
• The company may not use the net proceeds effectively.
• An active trading market for the company's shares may not be sustained.
• The offering may cause the trading price of the company's common stock to decrease.
• Lake Street may have a conflict of interest under FINRA Rule 5121.
• Future sales of substantial amounts of the company's common stock could adversely affect the market price of the company's common stock.
• Nasdaq may delist the company's common stock from its exchange.
• The company may not receive any additional funds upon the exercise of the common warrants.
• There is no public market for the common warrants or pre-funded warrants being offered by the company in this offering.
• The common warrants included in the units and in the pre-funded units are speculative in nature.
• Purchasers who purchase the company's securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.
• Sales of a substantial number of shares of the company's common stock by the company's stockholders in the public market could cause the company's stock price to fall.
• The rights of holders of the company's capital stock will be subject to, and could be adversely affected by, the rights of holders of the company's outstanding preferred stock and stock that may be issued in the future.
• There may be future sales of the company's securities or other dilution of the company's equity, which may adversely affect the market price of the company's common stock.
• The company has a large number of authorized but unissued shares of stock, which could negatively impact a potential investor if they purchased the company's common stock.
• A more active, liquid trading market for the company's common stock may not develop, and the price of the company's common stock may fluctuate significantly.
• The company's ability to use U.S. net operating loss carryforwards might be limited.
• The company does not intend to pay cash dividends on its common stock in the foreseeable future.
• Provisions in the company's charter documents and Delaware law may delay or deter a change-in-control transaction or limit the company's stockholders ability to obtain a favorable judicial forum for disputes with the company or its directors, officers, or employees.
• The company is a smaller reporting company under federal securities laws and the company cannot be certain whether the reduced reporting requirements applicable to such companies will make the company's common stock less attractive to investors.

Future Outlook

The company intends to use the net proceeds of this offering for working capital and for general corporate purposes, including for continued investments in its commercialization efforts.

Industry Context

The announcement highlights the ongoing need for innovative solutions in fluid management, particularly in heart failure, critical care, and pediatrics, where fluid overload is a significant concern. The company's focus on ultrafiltration as an alternative to diuretics aligns with the trend toward personalized and targeted therapies in healthcare.

Comparison to Industry Standards

• The document mentions Baxter's Prismaflex and Medtronic's Carpediem as competitors in the broader kidney replacement therapy market, but emphasizes Aquadex's unique position in ultrafiltration for fluid overload.
• The document cites several clinical trials (UNLOAD, CARRESS, AVOID-HF, REVERSE-HF) to support the clinical benefits of ultrafiltration compared to diuretics, a common industry benchmark.
• The document references cost savings associated with ultrafiltration compared to diuretic therapy, highlighting a key economic advantage.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's ability to fund its operations and commercialization efforts will be affected by the success of the offering.
• Hospitals and healthcare providers may benefit from the Aquadex System as an alternative therapy for fluid overload.
• Patients suffering from fluid overload could potentially benefit from improved treatment options.

Next Steps

• The company intends to continue actively monitoring the closing bid price for the company's common stock between now and June 4, 2024, and it will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.
• The Company intends to submit an IDE with the FDA in the first quarter of 2024, with U.S. commercialization of this product expected in the first quarter of 2025.
• The Company hopes to be fully enrolled by the end of 2024 with a total of 372 patients enrolled in the REVERSE-HF prospective, multicenter, randomized controlled trial (RCT).
• The Company hopes to complete analysis and to publish the results of the REVERSE-HF study in the second half of 2025.

Key Dates

Keywords

offering, units, common stock, warrants, pre-funded warrants, capital, commercialization, Nuwellis, Aquadex, Nasdaq